Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 30, 2016
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - September 30, 2016

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/30/16 - AB Science announces the filing of masitinib in the treatment of amyotrophic lateral sclerosis (ALS) to the European Medicines Agency [Tripoli Post, The (Libya)]
-AB Science SA, a pharmaceutical company specialized in the research, development and marketing of protein kinase inhibitors, announces today the acceptance and validation from the European Medicines Agency of the filing of masitinib in the treatment of amyotrophic lateral sclerosis, also known as Lou Gehrig`s disease, for conditional marketing...
9/30/16 - AbbVie's Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation
AbbVie, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for the investigational, pan-genotypic regimen of glecaprevir/ pibrentasvir for the treatment of patients with chronic hepatitis C virus who failed previous therapy with direct-acting antivirals in...
9/30/16 - Actinium Announces Pricing of Public Offering of Common Stock [Cihan News Agency (Turkey)]
-Actinium Pharmaceuticals, Inc., a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $1.25. H.C. Wainwright& Co. is acting as sole book-running ma
9/30/16 - Alder BioPharma Could Lead The Migraine Market; Brean Assumes With Buy Rating
Alder Biopharmaceuticals Inc is set to lead in the migraine market, at least according to Brean Capital, which has assumed coverage on the stock with a Buy rating and price target of $45. "We anticipate ALD403 US drug sales reaching $1 billion annually well before patent expiration in 2032," analyst Difei Yang wrote in a note. Yang noted that the
9/30/16 - Analgesic Solutions Announces Presentation of Signature Quantitative Data Surveillance System
Analgesic Solutions, a specialty consulting and clinical research company focused on the conduct of clinical trials in pain, announced today the presentation of its signature central statistical surveillance tool for the prospective monitoring of assay sensitivity in clinical trials at the International Association for the Study of Pain symposium
9/30/16 - Arrowhead Pharmaceuticals inks drug development deal with Amgen worth up to $673 million [The Wisconsin State Journal]
Sept. 30 Amgen, one of the world's leading biotechnology companies, is teaming with Arrowhead Pharmaceuticals to bring two drugs to market to treat cardiovascular disease in a deal worth more than $50 million to start, with the potential for an additional $600 million or more in the future. "We are thrilled to be working with Amgen." Arrowhead w
9/30/16 - Aurinia Announces That Voclosporin Achieves Primary Endpoints
Aurinia Pharmaceuticals Inc. a clinical stage biopharmaceutical company focused on the global immunology market, today announced that in addition to voclosporin achieving its primary endpoint of Complete Remission at 24 weeks, both doses of voclosporin when added to the current standard of care of Mycophenolate Mofetil and a forced oral...
9/30/16 - Award-winning New Mobile App FlexDek MAT Edition Provides Multiple Benefits to Pharmaceutical Companies, Insurance Providers and the Criminal Justice System [Cihan News Agency (Turkey)]
FlexDek MAT Edition, from Sober Network Inc., is designed to help patients receiving outpatient medication-assisted treatment for opioid use. The U.S. Substance Abuse and Mental Health Services Administration recently awarded First Place to FlexDek MAT Edition in its nationwide technology-based Opioid Recovery App Challenge. It is the second major.
9/30/16 - B2BGateway Provides Fully Integrated EDI Solution for Aptean Ross to Legacy Pharmaceutical Packaging
Rapid global growth in pharma packaging industry prompts leading supplier Legacy Pharmaceutical Packaging to further automate their supply chain processes thru cloud based EDI technology.
9/30/16 - Biopharmaceutical Company Executive Arrested and Charged with Insider Trading
BOSTON An executive of a California- based biopharmaceutical company was arrested yesterday and charged in U.S. District Court in Boston in connection with trading on insider information and profiting nearly $1 million. According to the indictment, from November 2011 to October 2014, Gadimian was the Senior Director of Regulatory Affairs at Puma.
9/30/16 - Biotechs and the Advancements in Cancer Oriented Clinical Trials
An important step in discovering new treatments for cancer and any sort of disease, as well as new ways to identify, analyze, and decrease the risk of disease, is by performing clinical trials. This shows researchers the many approaches we are capable of and while revealing the possible side effects of treatments. Actinium Pharmaceuticals Inc., Kit
9/30/16 - Boehringer Ingelheim and Sarah Cannon Research Institute launch strategic collaboration to develop novel immune-oncology therapies
Release date- 29092016- Ridgefield, Conn- Boehringer Ingelheim and Sarah Cannon Research Institute announced today a new strategic collaboration. This partnership brings together Boehringer Ingelheim's extensive experience in cancer drug development and Sarah Cannon's expertise and leadership in designing and optimizing clinical trials.
9/30/16 - Braeburn Pharmaceuticals and Camurus Enroll First Patients in a Phase 3 Efficacy Trial of CAM2038 for Treatment of Chronic Low Back Pain
PRINCETON, N.J. and LUND, Sweden, Sept. 30, 2016/ PRNewswire/ Braeburn Pharmaceuticals and Camurus announce that the first patients have been enrolled in the randomized, double-blind, placebo-controlled Phase 3 efficacy and safety trial of CAM2038 in patients with moderate to severe chronic low back pain that are currently being treated with opio
9/30/16 - Cancer Treatment Centers of America(R) at Midwestern Regional Medical Center Launches NEOADAPT Clinical Trial
Cancer Treatment Centers of America at Midwestern Regional Medical Center in suburban Chicago has begun a new phase II clinical trial using a chemotherapy-free approach for early-stage, non-metastatic triple positive breast cancer. The NEOADAPT clinical trial combines two HER2 targeted therapies, trastuzumab and pertuzumab, which are both FDA-..
9/30/16 - Cempra Announces Anti-NASH Effects of Solithromycin: Interim Results From Phase 2 Study [Arab News (Saudi Arabia)]
-Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced interim results showing anti-NASH effects in the first six nonalcoholic steatohepatitis patients dosed with solithromycin in a Phase 2 study. According to the...
9/30/16 - Children with High Grade Brain Tumors Will Soon be Able to Receive Cutting Edge Oncolytic Virus Therapy
Re-engineered Polio Virus with Dramatic Response in Adults to be Made Available to Children in a Phase 1 Clinical Trial Jointly Funded by The Andrew McDonough B+ Foundation and Solving Kids Cancer.
9/30/16 - Cimarron Medical Merges with Sun BioPharma in Reverse Merger Transaction
Cimarron Medical, Inc., a life science company, has merged with Sun BioPharma, Inc., a pre-clinical biopharmaceutical company, in a reverse merger transaction. Pursuant to the transaction, SB Acquisition Corporation, Inc., a wholly-owned subsidiary of Cimarron Medical or Merger Sub, merged with and into Sun BioPharma, with SBI remaining as the surv
9/30/16 - Cost-Effectiveness, High Demand and Patent Exclusivity to Drive the Biosimilars Market
The biosimilars market accounted for a value of USD 2.8 billion in 2015 and is estimated at USD 3.3 million in 2016. The market is expected to reach USD 7.3 billion by 2021, projecting a CAGR of 17.42% during the forecast period. The report highlights the North American, European, Asia-Pacific, and Latin American and Middle East& African markets.
9/30/16 - CYTORI THERAPEUTICS, INC. - 10-K/A - Management's Discussion and Analysis of Financial Condition and Results of Operations
We are a biotechnology company dedicated to the development of novel treatments and devices for a range of disorders using cells as a key part of the therapy. We are presently focused on developing our primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, urinary incontinence and thermal burns i
9/30/16 - Depomed Prevails in NUCYNTA Franchise ANDA Litigation Providing Market Exclusivity Until December 2025
Depomed, Inc. today announced that Judge Claire C. Cecchi of the United States District Court for the District of New Jersey has ruled in favor of Depomed in the company's patent litigation against all three filers of Abbreviated New Drug Applications for Depomed's NUCYNTA franchise. With the court s ruling, Depomed expects market exclusivity
9/30/16 - Eisai to Initiate Phase III Clinical Study of Anti-Cancer Agent Lenvatinib as Potential First-Line Therapy for Advanced Renal Cell Carcinoma
TOKYO, Sept 30, 2016 Eisai Co., Ltd. announced today the initiation of a global Phase III Clinical Study of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate in respective combination regimens with the anticancer agent everolimus and the anti-PD-1 antibody pembrolizumab as a potential first-line treatment for.
9/30/16 - EISAI TO INITIATE PHASE III CLINICAL STUDY OF ANTICANCER AGENT LENVATINIB AS POTENTIAL FIRST-LINE THERAPY FOR ADVANCED RENAL CELL CARCINOMA
Release date- 29092016- Eisai Co., Ltd. announced today the initiation of a global Phase III Clinical Study of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate in respective combination regimens with the anticancer agent everolimus and the anti-PD-1 antibody pembrolizumab as a potential first-line treatment for
9/30/16 - Enanta Pharmaceuticals Announces AbbVie's Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation
Enanta Pharmaceuticals, Inc.,, a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for AbbVie s investigational, pan-genotypic regimen of glecaprevir/...
9/30/16 - Endobronchial Cancer Market: & Investment Research Report 2020
Endobronchial Cancer Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014- 2020 Albany, NY 09/30/2016 Endobronchial cancer are characterized by small size, slow growth and usually misdiagnosed as asthma or chronic bronchitis due to their common symptoms. These cancers are usually benign and rare. Due to these reason
9/30/16 - Epizyme Appoints Pamela Strode as Vice President, Regulatory Affairs and Quality Assurance [Kuwait News Agency]
-Epizyme, Inc., a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has appointed Pamela Strode to the position of vice president of regulatory affairs and quality assurance. This next year will be transformational for Epizyme as we advance the clinical development of...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415